Document is current
Any future updates will be listed below
-
Authors
de las Heras, Javier https://orcid.org/0000-0001-5663-537X
Cebolla, Jorge J https://orcid.org/0000-0001-8727-9179
de Pedro, Sofía
Gómez-Barrera, Manuel https://orcid.org/0000-0001-8357-1279
Vitoria, Isidro https://orcid.org/0000-0003-4450-1213
-
Funding
Funding for this research was provided by:
Takeda Farmacéutica España S.A. (Takeda Farmacéutica España S.A.)
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 15 January 2026
First Online: 5 February 2026
Declarations
:
: Ethical approval is considered unnecessary according to national regulations, as this is not a study but a literature review, and nonpatient-level data are managed.
: Not applicable.
: JdH has received speaking and scientific consultancy fees from Sanofi and Takeda. JJC is a full-time employee of Takeda Farmacéutica España S.A. without stock options. SdP and MGB are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultant company specializing in the evaluation and assessment of health care interventions, which has received financial support to develop the literature review. IV declares no conflicts of interest. JdH and IV declare that they have not received financial support for drafting or reviewing the present manuscript.
